These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 21272606)
1. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Hangalapura BN; Oosterhoff D; Gupta T; de Groot J; Wijnands PG; van Beusechem VW; den Haan J; Tüting T; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD Vaccine; 2011 Mar; 29(12):2313-21. PubMed ID: 21272606 [TBL] [Abstract][Full Text] [Related]
2. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173 [TBL] [Abstract][Full Text] [Related]
4. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257 [TBL] [Abstract][Full Text] [Related]
6. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
7. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide]. Tan XH; Liu C; Wan YH Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369 [TBL] [Abstract][Full Text] [Related]
8. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Steitz J; Tormo D; Schweichel D; Tüting T Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477 [TBL] [Abstract][Full Text] [Related]
9. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Steitz J; Brück J; Knop J; Tüting T Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959 [TBL] [Abstract][Full Text] [Related]
11. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440 [TBL] [Abstract][Full Text] [Related]
12. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH Cells; 2020 Nov; 9(11):. PubMed ID: 33171765 [TBL] [Abstract][Full Text] [Related]
13. Improved efficacy of dendritic cell-based immunotherapy by cutaneous laser illumination. Chen X; Zeng Q; Wu MX Clin Cancer Res; 2012 Apr; 18(8):2240-9. PubMed ID: 22392913 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. Winter H; Hu HM; McClain K; Urba WJ; Fox BA J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488 [TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987 [TBL] [Abstract][Full Text] [Related]
16. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590 [TBL] [Abstract][Full Text] [Related]
17. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
19. Mannan-modified adenovirus as a vaccine to induce antitumor immunity. Ding ZY; Wu Y; Luo Y; Su JM; Li Q; Zhang XW; Liu JY; He QM; Yang L; Tian L; Zhao X; Deng HX; Wen YJ; Li J; Kang B; Wei YQ Gene Ther; 2007 Apr; 14(8):657-63. PubMed ID: 17287861 [TBL] [Abstract][Full Text] [Related]
20. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]